PreveCeutical Medical Inc.

PreveCeutical Medical Inc. is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

Recent News

  • PreveCeutical Announces Resignation of Board of Director Member

    Vancouver, British Columbia--(Newsfile Corp. - September 16, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces the resignation of Mr. Sachin Nanavati as a member of the Company's board of director (the "Board") for personal reasons effective September 16, 2022.Stephen Van Deventer, PreveCeutical's Chief Executive Officer, commented, "We thank Mr. Nanavati for considering to be on the Company's Board and wish him all the best."About PreveCeuticalPreveCeutical is a health sciences company that develops innovative options...

    2022-09-16 8:00 PM EDT
  • Appointment of Sachin Nanavati to PreveCeutical's Board of Directors

    Vancouver, British Columbia--(Newsfile Corp. - September 6, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces the appointment of Mr. Sachin Nanavati to the Company's board of directors (the "Board") effective September 1, 2022.Sachin is currently the Head of Industry, Healthcare with Google, Inc. He has vast knowledge and experience with healthcare and technology. Sachin was a founding member of Meta (Facebook)'s Health Team, which created a go-to-market strategy and narrative focused on...

    2022-09-06 7:00 AM EDT
  • PreveCeutical Enters into Credit Facility Agreement

    Vancouver, British Columbia--(Newsfile Corp. - July 22, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has entered into a $3 million credit facility agreement with the Company's Chief Executive Officer and Chair, Stephen Van Deventer, and the Company's former President and director, Kimberly Van Deventer (collectively, the "Lenders").Effective July 18, 2022, the Company entered into a convertible credit facility agreement with the Lenders in the aggregate principal amount of $3...

    2022-07-22 4:47 PM EDT
  • PreveCeutical Announces Change in Directors and Investor Awareness Services

    Vancouver, British Columbia--(Newsfile Corp. - May 27, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces the resignation of Mr. Anderson and Mr. Lotz and the appointment of Dr. Linnéa Olofsson to the Company's board of directors (the "Board").Resignation of DirectorsMr. Keith Anderson and Mr. Mark Lotz will be stepping down as directors of the Company effective May 31, 2022, to allow them more time to focus on their business.Appointment of DirectorThe Company...

    2022-05-27 4:30 PM EDT
  • Article Based on PreveCeutical's Pain Management Peptides Program Published in the British Journal of Pharmacology

    Vancouver, British Columbia--(Newsfile Corp. - May 9, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that the British Journal of Pharmacology (the "BJP"), published an article on April 29, 2022, on the design and development of its non-addictive analgesic program ("Analgesic Program") under the running title, "Short dynorphin-like peptide agonists for kappa opioid receptors" click here to see the report. The article has undergone full independent peer review.The Analgesic...

    2022-05-09 8:00 AM EDT
  • PreveCeutical Announces Debt Settlement and Conversion of Debt

    Vancouver, British Columbia--(Newsfile Corp. - March 30, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces that it has issued 11,600,000 common shares without par value in its capital (each, a "Share") to two non-arm's length creditors and an arm's length creditor of the Company at a deemed issuance price of $0.025 per Share.The Company entered into shares for debt settlement agreements with a current director and a company controlled by a current...

    2022-03-30 8:00 PM EDT
  • Settlement Reached in Tietz Class Action Lawsuit

    Vancouver, British Columbia--(Newsfile Corp. - January 13, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce the settlement of the proposed class action filed by Michael Tietz and Duane Loewen against the Company and many other parties in B.C. Supreme Court Action No. S197731, Vancouver Registry (the "Action").PreveCeutical commenced its own action against some of the defendants to the Action claiming damages for fraud, conspiracy, breach of contract, and other wrongs with...

    2022-01-13 8:00 AM EST
  • PreveCeutical Files International Patent Application for Sol-Gel Cannabinoid Formulation for Antiviral Use

    Vancouver, British Columbia--(Newsfile Corp. - November 29, 2021) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed an international patent application on November 19, 2021, entitled "Sol-Gel Cannabinoid Formulation and Antiviral Use" (the "Invention"), claiming priority from Australian patent application number 2020904291.The patent is for an invention that relates to an antiviral cannabinoid-containing sol-gel formulation and its use in the treatment or prevention of viruses such as Coronaviruses and...

    2021-11-29 8:00 AM EST